Russel Vought slated to receive veto authority over NIH grants

The U.S. Department of Health and Human Services announced plans to relocate a segment of the National Institutes of Health’s (NIH) research operations to a new campus later this year, a decision that proceeds despite formal objections from NIH Director Dr. Lawrence Tabak. The proposed move, outlined in a memorandum released Monday, aims to consolidate several specialized laboratories into a state‑of‑the‑art facility in Bethesda, Maryland, with the goal of enhancing interdisciplinary collaboration and modernizing infrastructure.

In a written statement, Dr. Tabak cited concerns that the relocation could disrupt ongoing clinical trials, strain personnel resources, and delay critical research on emerging health threats. He urged the agency to conduct a comprehensive impact assessment before finalizing the transfer. Agency officials responded that a detailed transition plan has already been drafted, including provisions for continuity of care, staff relocation assistance, and phased migration to minimize operational interruptions. The department indicated that the move is slated to begin in early 2027, with full implementation expected by 2029.

The pending relocation will be reviewed at an upcoming interagency oversight hearing, where both proponents and critics are expected to present evidence. Decision‑makers are slated to consider the director’s objections alongside projected benefits before confirming the final schedule.